You are here
Sustained Release Olanzapine
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43MH068925-01A1
Agency Tracking Number: MH068925
Amount:
$100,000.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Timeline
Solicitation Year:
2004
Award Year:
2004
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
AURITEC PHARMACEUTICALS, INC.
2275 E FOOTHILL BLVD
PASADENA, CA
91107
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: THOMAS Smith
Phone: (617) 461-6263
Email: TSMITH@AURITECPHARMA.COM
Phone: (617) 461-6263
Email: TSMITH@AURITECPHARMA.COM
Business Contact
Phone: (626) 376-4070
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The long-term goal of this research is to minimize morbidity associated with psychotic disorders by developing injectable long-acting formulations of olanzapine (Zyprexa/R), currently a leading atypical antipsychotic a
* Information listed above is at the time of submission. *